Rafael Holdings (RFL) Divestments (2021 - 2022)
Rafael Holdings' (RFL) quarterly Divestments came in at $48.2 million in Q4 2022, up 166206.9% year-over-year from N/an in Q4 2021, and up 178511.11% quarter-over-quarter from -$27000.0 in Q3 2022.
Powered by 
Analysis
Rafael Holdings (RFL) Divestments (2021 - 2022) Analysis & Trends
Rafael Holdings (RFL) has reported Divestments for 2 consecutive years, with $48.2 million the latest figure, recorded in Q4 2022.
- On a quarterly basis, Divestments rose 166206.9% year-over-year to $48.2 million in Q4 2022; TTM through Jul 2023 was $48.2 million, a 42729.2% increase from a year earlier, with the FY2023 full-year figure at $48.2 million, up 42729.2% from the prior year.
- Divestments was $48.2 million for Q4 2022 at Rafael Holdings, up from -$27000.0 in the prior quarter.
- Over five years, Divestments peaked at $48.2 million in Q4 2022 and troughed at -$31000.0 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Divestments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | Rafael Holdings | 133.65 Mn | 139.07 Mn | 171,000.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Oct 31, 2022 | 48.17 Mn |
| Jul 31, 2022 | -27,000.00 |
| Apr 30, 2022 | -26,000.00 |
| Jan 31, 2022 | -31,000.00 |
| Oct 31, 2021 | -29,000.00 |